Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ5B | ISIN: KYG4672N1198 | Ticker-Symbol: H7T2
Frankfurt
08.08.25 | 08:09
2,520 Euro
-11,27 % -0,320
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HUTCHMED CHINA LIMITED Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
2,3602,78008.08.

Aktuelle News zur HUTCHMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrUBS Cuts HUTCHMED TP to $36.9; Rating Buy2
FrHUTCHMED Collapses ~13%; 2024 NP Soars 16.6x but Rev. Slides3
DoHutchmed China interim profit jumps on joint venture stake disposal3
DoHutchmed China Ltd. Profit Advances In H1209BEIJING (dpa-AFX) - Hutchmed China Ltd. (HCM.L) revealed earnings for its first half that Increases, from last yearThe company's bottom line totaled $454.95 million, or $0.52 per share. This...
► Artikel lesen
DoHUTCHMED Ltd - 6-K, Report of foreign issuer1
DoHutchmed China Ltd - 2025 Interim Results-
HUTCHMED Aktie jetzt für 0€ handeln
DoHUTCHMED (00013): HUTCHMED REPORTS 2025 INTERIM RESULTS-
03.07.HUTCHMED to announce 2025 half-year results on August 71
03.07.HUTCHMED wird Halbjahresergebnisse 2025 am 7. August bekannt geben2
03.07.HUTCHMED (China) Limited: HUTCHMED to Announce 2025 Half-Year Financial Results1
03.07.HUTCHMED (00013): DATE OF BOARD MEETING AND ANNOUNCEMENT OF 2025 INTERIM RESULTS1
03.07.Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results-
02.07.HUTCHMED ernennt Deutsche Bank zum gemeinsamen Unternehmensmakler in London20
02.07.HUTCHMED appoints Deutsche Bank as joint corporate broker in London3
02.07.HUTCHMED (00013): UPDATE ON JOINT CORPORATE BROKERS IN LONDON1
02.07.Hutchmed China Ltd - Update on Joint Corporate Brokers in London-
30.06.HUTCHMED Ltd - 6-K, Report of foreign issuer1
30.06.HUTCHMED (China) Limited: HUTCHMED Announces China Approval for ORPATHYS in Combination with TAGRISSO for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy112- Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy - - The only all-oral combination treatment option...
► Artikel lesen
30.06.HUTCHMED (00013): TOTAL VOTING RIGHTS-
30.06.HUTCHMED (00013): HUTCHMED ANNOUNCES CHINA APPROVAL FOR ORPATHYS IN COMBINATION WITH TAGRISSO FOR THE TREATMENT OF LUNG CANCER PATIENTS WITH MET AMPLIFICATION ...2
Weiter >>
169 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1